- PMID: 38546067
- DOI: 10.31557/APJCP.2024.25.3.839
Abstract
Objective: The purpose of this study is to comparatively analyze the anticancer properties of Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Tetrahydrocannabivarin (THCV) using In silico tools.
Methods: Using SwissADME and pkCSM, the physicochemical and pharmacokinetics properties of the cannabinoids were evaluated. Protox-II was utilized for the assessment of their cytotoxicity. The chemical-biological interactions of the cannabinoids were also predicted using the Way2Drug Predictive Server which comprises Acute Rat Toxicity, Adver-Pred, CLC-Pred, and Pass Target Prediction.
Results: Both physicochemical and drug-likeness analysis using SwissADME favored THCV due to high water solubility and lower MLOGP value. On the other hand, ADMET assessment demonstrated that THC and CBD have good skin permeability while both THC and THCV exhibited better BBB permeability and have low inhibitory activity on the CYP1A2 enzyme. Furthermore, toxicity predictions by Protox-II revealed that CBD has the lowest probability of hepatotoxicity, carcinogenicity, and immunotoxicity. Contrarily, it has the highest probability of being inactive in mutagenicity and cytotoxicity. Additionally, CLC results revealed that CBD has the highest probability against lung carcinoma. The rat toxicity prediction showed that among the cannabinoids, THCV had the lowest LD50 concentration in rat oral and IV.
Conclusion: Overall, in silico predictions of the three cannabinoid compounds revealed that they are good candidates for oral drug formulation. Among the three cannabinoids, THCV is an excellent anticancer aspirant for future chemotherapy with the most favorable results in drug-likeness and ADMET analysis, pharmacological properties evaluation, and cytotoxicity assessment results. Further study on bioevaluation of compounds is needed to elucidate their potential pharmacological activities.
Keywords: ADME, Anticancer drugs, Cytotoxicity, Virtual screening, cannabinoids
Similar articles
-
Cannabinoids Tetrahydrocannabinol, Cannabinol, Cannabidiol, Tetrahydrocannabivarin and 11-nor-9-carboxy-∆9-THC in Hair.J Anal Toxicol. 2022 May 20;46(5):487-493. doi: 10.1093/jat/bkab068.PMID: 34153110
-
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944.PMID: 25257544 Free PMC article. Review.
-
Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats.Int J Pharm. 2022 Aug 25;624:122016. doi: 10.1016/j.ijpharm.2022.122016. Epub 2022 Jul 18.PMID: 35863593 Free PMC article.
-
Comparative metabolism of THCA and THCV using UHPLC-Q-Exactive Orbitrap-MS.Xenobiotica. 2023 Jan;53(1):46-59. doi: 10.1080/00498254.2023.2194981. Epub 2023 Apr 10.PMID: 36951512
-
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442. Epub 2007 Sep 10.PMID: 17828291 Free PMC article. Review.